| Autor: |
Eder, Joseph, Elias, Anthony, Ayash, Lois, Wheeler, Catherine, Shea, Thomas, Schnipper, Lowell, Frei, Emil, Antman, Karen, Eder, J P, Elias, A D, Ayash, L, Wheeler, C A, Shea, T C, Schnipper, L E, Frei, E 3rd, Antman, K H |
| Předmět: |
|
| Zdroj: |
Cancer Chemotherapy & Pharmacology; Jan1991, Vol. 29 Issue 1, p61-65, 5p |
| Abstrakt: |
Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granulocytopenia of less than 500/microliters that lasted for greater than 14 days or thrombocytopenia of less than 25,000/microliters that lasted for greater than 14 days was the target dose-limiting toxicity in the absence of nonhematologic grade 4 toxicity. The maximal tolerated dose was 7 g/m2. Three patients died. Of 21 evaluable patients, 9 responded, including 8/9 who had experienced disease progression during prior oxazaphosphorine-containing combination chemotherapy. Clinically meaningful responses were observed in patients who had demonstrated clinical resistance to an oxazaphosphorine drug given at lower doses. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink